fig3
Figure 3. Schematic representation of NO generating tumour vasculature targeted drug delivery systems. Copper ion-chelated porphyrin triggers tumour vasculature specific release of NO causing local vasodilation, whereas RGD peptide causes αvβ3 mediated tumour cell-specific nanoparticle uptake. The drug is released specifically within the cancer cells where the cytoplasmic levels of GSH is higher than normal cells. NO: nitric oxide; GSH: glutathione; RSNO: S-Nitroso alkane NP: nanoparticle; RGD: arginylglycylaspartic acid
